Table 1.

Frequency of mutations and estimated risk of EOC in candidate genes (p<0.05) from targeted sequencing and exome sequencing

Set*	Histotype	Gene	Controls		Cases		Or (95% CI)	P value
			No.	%	No.	%
TS	Overall	POLK	9	0.17	29	0.52	3.04 (1.43 to 6.43)	0.0037
		PALB2	6	0.12	19	0.34	3.10 (1.23 to 7.78)	0.016
		SLX4	4	0.08	13	0.23	3.08 (1.00 to 9.48)	0.0049
		FBXO10	9	0.17	3	0.053	0.30 (0.08 to 1.11)	0.071
		Non-carrier	5174	99.5	5492	98.8
	HGSOC	POLK	9	0.17	27	0.53	3.17 (1.48 to 6.79)	0.003
		PALB2	6	0.12	18	0.35	3.30 (1.30 to 8.38)	0.012
		SLX4	4	0.08	13	0.25	3.51 (1.13 to 10.9)	0.029
		FBXO10	9	0.17	3	0.059	0.32 (0.09 to 1.18)	0.086
		Non-carrier	5174	99.5	5062	98.8
ES	Overall	POLK	7	0.77	6	0.72	0.94 (0.32 to 2.82)	0.92
		PALB2	2	0.22	3	0.36	1.65 (0.28 to 9.93)	0.58
		SLX4	0	0	2	0.24	NA
		FBXO10	1	0.11	0	0
		Non-carrier	903	98.9	818	98.7
	HGSOC	POLK	7	0.77	6	0.72	0.94 (0.32 to 2.82)	0.92
		PALB2	2	0.22	3	0.36	1.66 (0.28 to 9.94)	0.58
		SLX4	0	0	2	0.24	NA
		FBXO10	1	0.11	0	0	NA
		Non-carrier	903	98.9	817	98.7

*TS: targeted sequencing; ES: exome sequencing.

EOC, epithelial ovarian cancer; HGSOC, high-grade serous ovarian cancer; OCAC, Ovarian Cancer Association Consortium.